Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine…

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 • VYD2311 met all primary and secondary endpoints comparing

Event · Clinical / regulatory
Product
VYD2311
Milestone
topline data
Indication
COVID-19

Facts are quoted from the filing text and checked against it.

Original reporting
Published Sep 29, 2026, 11:26 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 11:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$IVVD
Bullish
high confidence
Mentioned
$IVVD
Relevance
9/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IVVDBullishMed
01

Why it matters

The data suggest a clear safety advantage over existing mRNA vaccines, which could position VYD2311 as a complementary prophylactic option.

02

Market read

First‑report of pivotal trial results for a Nasdaq biotech; likely to move IVVD stock and influence the antiviral antibody segment.

03

What to watch

Potential competition from next‑generation mRNA boosters and the need for large‑scale manufacturing capacity.

Relevance 9/10Novelty 9/10Timing: today, following the Sep 29 8‑K filing

Background

The filing is an SEC Form 8‑K announcing the first Phase 3 data for VYD2311 and outlining next steps toward a BLA submission.

Company-level read

Ticker impact

$IVVDBullishHigh confidence
Context

Invivyd disclosed positive Phase 3 LIBERTY trial results showing safety and tolerability superiority of VYD2311 versus an mRNA COVID‑19 vaccine and announced FDA BLA plans.

Expected impact

upward pressure as the market prices in the favorable safety profile and accelerated approval pathway.

Evidence & confidence

First‑report of pivotal Phase 3 data for a Nasdaq‑listed biotech; such news historically drives significant short‑term price gains.

Market effects

May lift other COVID‑19 monoclonal antibody developers and increase investor interest in antiviral biotech sector.

Positive for US biotech indices and Nasdaq biotech exposure.

Limited to biotech investors; no broad macro impact.

Counterpoint

If regulatory hurdles delay accelerated approval, the initial hype could fade and the stock may face sell‑off.

Key entities

  • Invivyd, Inc.

    Nasdaq‑listed biotech developing VYD2311 monoclonal antibody.

  • FDA

    U.S. agency reviewing the upcoming BLA for accelerated approval.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.